The Canonsburg, Pennsylvania-based company also raised the 2024 sales outlook for its new product range, including Breyna - a biosimilar to Astrazeneca's asthma drug Symbicort - to between $500 ...

Drugs covered by the cap include Airsupra, which contains albuterol and budesonide; Bevespi Aerosphere; Breztri Aerosphere; ...

Column written by Lindsay Bishop RN] Going back to school in September is an exciting and busy time for both students and ...

The cap is effective June 1 and will apply to the company’s entire range of inhaler products used to treat asthma and chronic obstructive pulmonary disease, including inhalers Symbicort ...

A US court has upheld AstraZeneca’s patents on its respiratory drug Symbicort, blocking cheaper competition for the ageing blockbuster. The US District Court for the Northern District of West ...

Symbicort brought in worldwide sales of $2.7 billion last year, with $1.1 billion of that coming from the US market, where an authorised generic sold under license from AZ has been available since ...

Seretide/Advair (fluticasone propionate + salmeterol; GlaxoSmithKline) and Symbicort (budesonide + formoterol fumarate dihydrate; AstraZeneca), which are ICS–LABA combinations, are other popular ...

Asthma–chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) is a commonly encountered yet loosely defined clinical entity. ACOS accounts for approximately 15–25% of the ...